Novo Nordisk
2025.03.12
12:33
Jefferies: Lowered Novo Nordisk's target price from 515 Danish kroner to 450 Danish kroner.
2025.03.06
14:54
Novo Nordisk (NVO.N): Risk costs are expected to be around 35% by 2025 and around 32% in the medium term.
2025.03.03
14:00
Goldman Sachs has included AstraZeneca, Novo Nordisk and Rio Tinto on its European "confidence list".
2025.02.25
08:19
Huatai Securities: There is a large gap in global GLP-1 products, and the M&A wave is expected to continue
Huatai Securities believes that GLP-1 has shown great market potential, and currently only Novo Nordisk and Eli Lilly are the leading MNCs in sales overseas, but they have not yet formed a complete product matrix. Other MNC products are still in the clinical stage, the competition landscape has not yet been finalized, and there is a large gap in products. Since 2004, there have been frequent overseas transactions of domestic GLP-1. We believe that the competitiveness of domestic GLP-1 products is not inferior to that of overseas products. Among them, there are many high-quality assets with leading clinical progress in targets such as GLP-1 oral small molecules, GLP-1/GIP, GLP-1/GIP/GCGR, GLP-1/GCGR/FGF21, and ActRII, which are expected to enter the global market with the help of BD in the future.
2025.02.21
23:12
Novo Nordisk (NVO.N): All doses of semaglutide approved by the U.S. Food and Drug Administration (FDA) are continuing to ship, meeting or exceeding expected U.S. demand.
22:33
Trump Media & Technology Group (DJT.O) rose 2% after its board voted to move forward with expansion plans, while Novo Nordisk (NVO.N) rose 4.9% after the U.S. Food and Drug Administration (FDA) said the shortage of Ozempic had been resolved.
22:23
Novo Nordisk rose nearly 6% in premarket trading
Novo Nordisk rose nearly 6% in premarket trading after the U.S. Food and Drug Administration (FDA) said the shortage of semaglutide injection Ozempic has been resolved.
22:20
Novo Nordisk (NVO.N) rose 5.5% in premarket trading after the U.S. Food and Drug Administration (FDA) said the shortage of semaglutide injection Ozempic has been resolved.
2025.02.06
00:38
ECB board member Centeno: Novo Nordisk's planned IPO will have "good results" for the banking sector and competitiveness.
2025.02.05
17:04
Novo Nordisk's US stock rose more than 4% before the market opened
Novo Nordisk's U.S. shares rose more than 4% in pre-market trading as its weight loss drug Wegovy's sales more than doubled in the fourth quarter of last year.
17:04
Novo Nordisk's US stock rose more than 4% before the market opened
Novo Nordisk's U.S. shares rose more than 4% in pre-market trading as its weight loss drug Wegovy's sales more than doubled in the fourth quarter of last year.
17:03
Novo Nordisk (NVO.N) shares rose more than 4% in pre-market trading in the U.S. as its weight loss drug Wegovy sales more than doubled in the fourth quarter of last year.
17:03
Novo Nordisk (NVO.N) shares rose more than 4% in pre-market trading in the U.S. as its weight loss drug Wegovy sales more than doubled in the fourth quarter of last year.
2025.01.29
03:32
Novo Nordisk: The U.S. Food and Drug Administration (FDA) approved Ozempic to reduce the risk of worsening kidney disease. Ozempic can be used to reduce the risk of death from heart disease.
2025.01.24
22:31
U.S. stocks opened, with the Dow Jones Industrial Average down 0.07%, the S&P 500 Index up 0.03%, and the Nasdaq Composite Index up 0.15%. Novo Nordisk (NVO.N) rose 10.62% after clinical trials showed that its weight loss drug Amycretin can reduce weight by 22%. Meta Platforms (META.O) fell 0.19%, CEO Zuckerberg plans to significantly expand the artificial intelligence team. Nvidia (NVDA.O) rose 1%.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Intel's US stock rose more than 10% in the night trading

2025-03-12

360 launches DS large model security solution to protect the development of DeepSeek

2025-03-12

JD.com's revenue in Q4 2024 is expected to be 347 billion yuan

2025-03-06

Daiwa Securities raised Alibaba Group's target price from HK$165 to HK$175

2025-03-07

Ouye Semiconductor completed B2 round of financing of hundreds of millions of yuan to promote large-scale application of products

2025-03-13

ASIA TECH WIRE

Grasp technology trends

Download